Rosiglitazone reduces hepatic fat content

Rosiglitazone reduces hepatic fat content

Detalhes bibliográficos
Main Authors:	Buckingham, R, Toseland, C, Draper, N, Clarke, K
Formato:	Journal article
Publicado em:	2000

Registos relacionados

Rosiglitazone prevents ischaemic injury in the obese Zucker rat heart
Por: Sidell, R, et al.
Publicado em: (2001)

Leukemia and rosiglitazone
Por: Irfan Yavasoglu, et al.
Publicado em: (2016-03-01)

Sirt1 and Sirt6 mediate beneficial effects of rosiglitazone on hepatic lipid accumulation.
Por: Soo Jin Yang, et al.
Publicado em: (2014-01-01)

Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice.
Por: How, O, et al.
Publicado em: (2007)

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Por: Kahn, SE, et al.
Publicado em: (2006)

The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.
Por: Lygate, C, et al.
Publicado em: (2003)

Rosiglitazone-associated fractures in type 2 diabetes
Por: Kahn, SE, et al.
Publicado em: (2008)

Possible modulation of the antidiabetic effect of rosiglitazone by buspirone
Por: Wafaa R. Mohamed, et al.
Publicado em: (2012-06-01)

Incidence of diabetes following ramipril or rosiglitazone withdrawal
Por: Holman, R, et al.
Publicado em: (2011)

Rosiglitazone reduces diabetes angiopathy by inhibiting mitochondrial dysfunction dependent on regulating HSP22 expression
Por: Lingling Yu, et al.
Publicado em: (2023-04-01)

Guidance on rosiglitazone for type 2 diabetes mellitus.
Por: Matthews, DR
Publicado em: (2001)

Incidence of diabetes following ramipril or rosiglitazone withdrawal.
Por: Investigators, D
Publicado em: (2011)

Isolation, Synthesis and Characterization of Rosiglitazone Maleate Impurities
Por: Singamsetty Radha Krishna, et al.
Publicado em: (2008-01-01)

Budget impact of rosiglitazone in type 2 diabetes
Por: Orietta Zaniolo, et al.
Publicado em: (2007-03-01)

Safety and efficacy of rosiglitazone in the elderly diabetic patient
Por: Adie Viljoen, et al.
Publicado em: (2009-04-01)

The autophagic regulation of rosiglitazone-promoted adipocyte browning
Por: Yue Li, et al.
Publicado em: (2024-06-01)

Hepatic Angiomyolipoma with Minimal Intratumoral Fat Content
Por: Masataka Banshodani, et al.
Publicado em: (2009-11-01)

Rosiglitazone , Metformin or both for Treatment of Polycystic Ovary Syndrome
Por: Mohammed A.Taher, et al.
Publicado em: (2017-03-01)

Rosiglitazone , Metformin or both for Treatment of Polycystic Ovary Syndrome
Por: Mohammed A.Taher, et al.
Publicado em: (2017-03-01)

Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
Por: Colin R Dormuth, et al.
Publicado em: (2009-06-01)

RP-HPLC Method for the Simultaneous Estimation of Rosiglitazone and Gliclazide in Tablets
Por: G. Rathinavel, et al.
Publicado em: (2009-01-01)

Rosiglitazone ameliorates diffuse axonal injury by reducing loss of tau and up-regulating caveolin-1 expression
Por: Yong-lin Zhao, et al.
Publicado em: (2016-01-01)

Effect of Rosiglitazone on Coronary Angiogenesis in Diabetic and Control Rats
Por: Ensieh Salehi, et al.
Publicado em: (2011-06-01)

Rosiglitazone as an option for patients with acromegaly: a case series
Por: Bahena-García Ana, et al.
Publicado em: (2011-05-01)

Simpson's paradox visualized: The example of the Rosiglitazone meta-analysis
Por: Schumacher Martin, et al.
Publicado em: (2008-05-01)

The impact of acute rosiglitazone on insulin pharmacokinetics at the blood‐brain barrier
Por: Demi C. Galindo, et al.
Publicado em: (2020-07-01)

High Concentrations of Rosiglitazone Reduce mRNA and Protein Levels of LRP1 in HepG2 Cells
Por: Alejandro N. Rondón-Ortiz, et al.
Publicado em: (2017-11-01)

Correction: Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin.
Por: Colin R. Dormuth, et al.
Publicado em: (2010-01-01)

Lipid metabolome-wide effects of the PPARγ agonist rosiglitazones⃞
Por: Steven M. Watkins, et al.
Publicado em: (2002-11-01)

Preventive effects of Salvia officinalis leaf extract on insulin resistance and inflammation in a model of high fat diet-induced obesity in mice that responds to rosiglitazone
Por: Mohamed R. Ben Khedher, et al.
Publicado em: (2018-01-01)

Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria
Por: Rosauro Varo, et al.
Publicado em: (2017-05-01)

Co-Administration of Conjugated Linoleic Acid and Rosiglitazone Increases Atherogenic Co-Efficient and Alters Isoprenaline-Induced Vasodilatation in Rats Fed High Fat Diet
Por: Chai, Boon Kheng, et al.
Publicado em: (2018)

Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats.
Por: Soo Jin Yang, et al.
Publicado em: (2011-01-01)

Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet.
Por: Vladimir Kus, et al.
Publicado em: (2011-01-01)

Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: a possible role for adiponectin and miR-21?
Por: Martine C. Morrison, et al.
Publicado em: (2017-06-01)

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
Por: Lachin, J, et al.
Publicado em: (2011)

Prenatal Rosiglitazone Administration to Neonatal Rat Pups Does Not Alter the Adult Metabolic Phenotype
Por: Hernan Sierra, et al.
Publicado em: (2012-01-01)

Correction: Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin
Publicado em: (2010-01-01)

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
Por: Zinman, B, et al.
Publicado em: (2010)

The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
Por: Tan, G, et al.
Publicado em: (2005)